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Abstract: Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events 
during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). 
Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on 
the market and three different compounds, namely abciximab, tiroﬁ  ban, and eptiﬁ  batide, have 
been approved for clinical use. Abciximab has been investigated in the clinical ﬁ  eld far more 
extensively than the other GPIIb/IIIa inhibitors. Abciximab is an anti-integrin Fab fragment of 
a human – mouse chimeric monoclonal antibody with high afﬁ  nity and a slow dissociation rate 
from the GP IIb/IIIa platelet receptor. Abciximab, given shortly before the coronary intervention, 
is superior to placebo in reducing the acute risk of ischemic complications (EPIC, EPISTENT, 
EPILOG trials); moreover, in the ISAR-REACT 2 study abciximab has been shown to reduce 
the risk of adverse events in patients with non ST-segment elevation ACS who are undergo-
ing PCI even after optimal pre-treatment with 600 mg of clopidogrel. Finally, abciximab has 
been also used in abciximab-coated stent, with only bolus administration regimen and for 
direct intracoronary use with promising results that may extend and/or modify its current use 
in clinical practice in future.
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Platelet reactivity plays a pivotal role in the pathogenesis of ischemic cardiovascular 
disorders (Kabbani et al 2001).
Both platelet activation and aggregation have been shown to be heightened in 
the setting of acute coronary syndromes (ACS) and current evidence supports the 
concept that spontaneous (Kabbani et al 2003) or drug-modulated (Matetzky et al 
2004) propensity to platelet-clot formation is a strong and independent predictor of 
clinical outcome. Blocking platelet aggregation with various agents acting on dif-
ferent molecular pathways has been consistently demonstrated to be of unequivocal 
beneﬁ  t in broad population of patients. Among the proposed pharmacological targets 
for antiplatelet therapy, the glycoprotein (GP) IIb/IIIa receptor continues to be among 
the most promising (Topol et al 1999). GPIIb/IIIa, the αIIB/ß3 integrin, is a platelet-
speciﬁ  c adhesion receptor with broad speciﬁ  city for a number of ligands, most notably 
ﬁ  brinogen, von Willebrand factor (vWF), and prothrombin. αIIB/ß3 integrin is the 
most abundant platelet membrane GP. GPIIb/IIIa mediates the formation of platelet 
aggregates via vWF and soluble ﬁ  brinogen. Platelet stimulation by soluble agonists 
(thrombin, adenosine diphoshate, and thromboxane A2) causes conformational changes 
of the receptor with subsequent transformation from a low- into a high-afﬁ  nity state, 
allowing for ligand (circulating ﬁ  brinogen or vWF) binding. This conformational 
change of GPIIb/IIIa is not due to any direct action of the agonists on the receptor 
but results directly from receptor-mediated stimulation of intracellular signalling 
pathways that enhance ligand-afﬁ  nity of GP IIb/IIIa. All GP IIb/IIIa antagonists react 
with the resting and active forms of αIIB/ß3 integrin and therefore all agents bind to 
non-stimulated and stimulated platelets, although with different afﬁ  nities towards the Biologics: Targets & Therapy 2008:2(1) 30
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receptor and in different binding sites (Schror et al 2003). 
The GPIIb/IIIa inhibitors are a class of agents blocking the 
binding of ﬁ  brinogen to activated GPIIb/IIIa, thereby inhib-
iting platelet-platelet interaction and thrombus formation. 
GPIIb/IIIa inhibitors have been shown to reduce secondary 
complications following percutaneous coronary intervention 
(PCI). Three GPIIb/IIIa inhibitors, abciximab, tiroﬁ  ban, 
and eptiﬁ  batide, have been approved for clinical use in the 
United States and other countries (Table 1). They are given 
by intravenous administration whereas development of oral 
GP 2b/3a inhibitors has been discontinued due to negative 
or even paradoxical ﬁ  ndings in clinical trials.
This paper will focus on abciximab which provided 
robust, consistent, and signiﬁ  cant reduction in death or 
myocardial infarction (MI) in several PCI trials.
Pharmacodynamics and
pharmacokinetics of abciximab
Abciximab is an anti-integrin Fab fragment of a human – mouse 
chimeric monoclonal antibody with high afﬁ  nity and a slow 
dissociation rate from the GPIIb/IIIa platelet receptor (Mager 
et al 2003; Schror et al 2003; Gowda et al 2004; Silva et al 
2004; Atwater et al 2005). It has a short plasma half-life of 
10–30 minutes, but a long biologic half-life due to its strong 
afﬁ  nity to the GPIIb/IIIa receptor (67% bound to the receptor). 
It remains bound in circulation for up to 15 days with minimal 
residual activity. Its receptor occupancy is 30% at 8 days and 
10% at 15 days. Despite prolonged receptor occupancy, platelet 
function returns to baseline 12–36 hours after therapy cessa-
tion mainly due to rapid platelet turnover (Mager et al 2003; 
Schror et al 2003; Gowda et al 2004; Silva et al 2004; Atwater 
et al 2005). Abciximab-coated platelets can be detected in the 
circulation for at least 2 weeks after treatment. Complete recep-
tor blockade is obtained at approximately 5 μg/mL (100 nM). 
The binding site of abciximab is located at the ß-chain of the 
GPIIb/IIIa receptor and is different from the binding site for 
the low-molecular-weight inhibitors eptiﬁ  batide and tiroﬁ  ban 
(Mager et al 2003; Schror et al 2003; Silva et al 2004; Gowda 
et al 2004; Atwater et al 2005). The advantage of low plasma 
concentrations and the high receptor afﬁ  nity allows revers-
ibility of signiﬁ  cant bleeding time with platelet transfusions. 
Mechanistically, the large antibody fragment (molecular weight 
about 50 kD) causes a steric hindrance of access of ligands to 
their binding pocket. This also explains its almost equimolar 
potency (kD: 7 nM) for inhibition of the other ß3 integrin av/ß3, 
the vitronectin receptor at the surface of vascular cells, ie, the 
endothelium and vascular smooth muscle. At lower afﬁ  nity (kD: 
160 nM), abciximab also interacts with the activated MAC-1 
receptor on leukocytes (Mager et al 2003; Schror et al 2003; 
Gowda et al 2004; Silva et al 2004; Atwater et al 2005). These 
additional interactions with other integrins are not generally 
shared by other two low-molecular-weight antagonists. The 
clinical relevance of occupancy of non-GP IIb/IIIa receptors 
by abciximab has not been established. Abciximab has been 
shown to elicit an antibody response, particularly after read-
ministration, most likely because of its large size and murine 
origin. On repeat dosing, this antigenicity of abciximab may 
increase the risk of thrombocytopenia (Aster 2005).
Principal clinical studies using 
abciximab
Given shortly before the PCI, abciximab is superior to 
placebo in reducing the acute risk of ischemic complica-
tions (the Evaluation of 7E3 for the Prevention of Ischemic 
Complications – EPIC – study [The EPIC Investigators 
1994]; the Evaluation in Percutaneous Transcateter Coronary 
Angioplasty to Improve Long-term Outcome with Abciximab 
GP IIb/IIIa blockade – EPILOG – study [The EPILOG Inves-
tigators 1997]; the Evaluation of Platelet IIb/IIIa Inhibitor for 
Stenting –EPISTENT – study [The EPISTENT Investigators 
1998], Table 2). Two studies, CAPTURE (The CAPTURE 
Investigators 1997) (the Chimeric 7E3 Antiplatelet in 
Unstable Angina Refractory to Standard Treatment study) 
and GUSTO IV-ACS (The GUSTO IV-ACS Investigators 
2001) (the Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries 
study) have evaluated the efﬁ  cacy and safety of abciximab 
in the context of different management strategies for patients 
with non ST-segment elevation ACS (NSTEACS). In the 
CAPTURE (The CAPTURE Investigators 1997) study, 1265 
patients who were admitted with unstable angina and who 
continued to have refractory ischemia underwent cardiac 
catheterization. Patients who were deemed good candidates 
for PCI were randomized into abciximab therapy for 18–24 
hours before angioplasty and 1 hour after, or placebo treat-
ment with coronary angioplasty. The primary composite end 
point at 30 days of death, MI, or urgent repeat intervention 
for recurrent ischemia was signiﬁ  cantly less in patients who 
received abciximab (11.3% abciximab vs 15.9% placebo; 
p = 0.012). The majority of beneﬁ  t with abciximab was 
derived with reduction of peri-procedural MI (2.6% abcix-
imab vs 5.5% placebo; p = 0.009), and a reduction in MI 
prior to intervention was also observed (0.6% abciximab vs 
2.1% placebo; p = 0.0029). However, this favorable effect 
was lost at 6 months in the whole cohort of patients. It should 
be emphasized that greater beneﬁ  t from platelet GPIIb/IIIa Biologics: Targets & Therapy 2008:2(1) 31
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inhibitor therapy is mainly seen in NSTEACS patients who 
present with elevated baseline cTnT levels. Indeed, in this 
subset of patients the rates of death or MI at 6 months were 
profoundly reduced in the abciximab-treated cohorts even at 
6 months (9.5% abciximab vs 23.9% placebo; p = 0.002).
The GUSTO IV-ACS (The GUSTO IV-ACS Investigators 
2001) trial showed no signiﬁ  cant beneﬁ  t to abciximab in the 
medical management of NSTEACS. In the GUSTO IV-ACS 
(The GUSTO IV-ACS Investigators 2001), PCI was discour-
aged by the protocol and ultimately it was performed only 
in 1.6% of patients within 48 hours and in 19% within 30 
days. Abciximab was associated with a trend towards higher 
early mortality (at 48 hours) than in the placebo arm. There 
was also a lack of any therapeutic beneﬁ  t at 30 days. Thus, 
the American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines (Braunwald et al 2002) give a 
class III recommendation (either not effective or potentially 
harmful) for the addition of abciximab to standard anti-
thrombotic therapy in patients in whom PCI is not planned. 
The negative results of the GUSTO IV-ACS trial may be 
explained by the lack of access to timely revascularization 
which is in keeping with the results of several other trials 
based on the use of GPIIb/IIIa inhibitors. All these landmark 
investigations were conducted in the pre-clopidogrel era. 
Thus, patients were randomized to abciximab vs placebo on 
a background of aspirin alone as antiplatelet agent.
To assess the hypothesis that abciximab may be a useful 
therapy in patients with NSTEACS undergoing PCI, even 
after pretreatment with a 600 mg loading dose of clopidogrel, 
the ISAR-REACT 2 (Kastrati et al 2006) (the Intracoronary 
Stenting and Antithrombotic Regimen: Rapid Early Action 
for Coronary Treatment study) has been designed. Patients 
with an episode of angina (with an accelerating pattern, or 
prolonged, or recurrent episodes at rest, or with minimal 
effort) within the preceding 48 hours, accompanied by an 
elevated troponin level or a new ﬁ  nding of ST-segment 
depression or new or presumed new bundle-branch block 
undergoing PCI were enrolled, treated with 500 mg of oral or 
intravenous aspirin plus 600 mg clopidogrel, and randomized 
to abciximab or placebo. As result, a 25% reduction of the 
risk of recurrent ischemic events among patients assigned 
to abciximab was observed. Notably, the gradient in favor 
of abciximab was seen for all components of the primary 
end point (death, MI, and target vessel revascularization), 
although none reached statistical signiﬁ  cance when con-
sidered individually. The adverse event rate observed in 
patients without an elevated troponin level was similar to 
that seen previously in the ﬁ  rst ISAR-REACT trial (Kastrati 
et al 2004) (Table 2). In contrast, among patients with an 
elevated troponin level, the risk of recurrent ischemic events 
was considerably higher than that in those without elevated 
troponin levels and was reduced by 29% by abciximab.
When taken together current evidence suggests that the 
beneﬁ  t of abciximab over placebo is proportional to the risk 
status of the patients. This notion should be kept in mind when 
interpretating the apparently negative results observed with 
abciximab in the ISAR-REACT study (Kastrati et al 2004).
Several trials have been conducted to test the role of abcix-
imab in the setting of ST-segment elevation MI (STEMI). 
Recently, a meta-analysis has been published reporting 
3-years follow-up data of 1101 patients presenting for pri-
mary PCI and stenting of STEMI randomized to abciximab 
or placebo (Montalescot et al 2007). This analysis included 
data from ADMIRAL (Montalescot et al 2001) (the Abcix-
imab before Direct Angioplasty and Stenting in Myocardial 
Infarction regarding Acute and Long-term Follow-up study), 
ISAR-2 (Neumann et al 2000), and ACE (Antoniucci et al 
2003) (the Abciximab and Carbostent Evaluation study) trials. 
Table 1 Pharmacological data of principal GPIIb/IIIa inhibitors
Parameter Abciximab  Tiroﬁ  ban  Eptiﬁ  batide
Molecular weight (Da)  ∼50000  ∼490  ∼800
Receptor selectivity     
 GPIIb/IIIa  High  High  High
 MAC-1  High  No  No
Molecular mechanism  Monoclonal antibody with high afﬁ  nity   Competitive inhibitor  Competitive inhibitor
  for GPIIb/IIIa receptor
Clearance Platelet  binding  Renal  (60%)  + biliar (40%)  Renal (90%)
Half-life (h)     
 plasma  0.5  2  3
 platelet  4  No  No
Dissociation constant (nmol/L)  ∼5  ∼15  ∼120
Antigenicity Possible  No  No
Reversibility of effect (h)  72–96  4  4–6Biologics: Targets & Therapy 2008:2(1) 32
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The primary endpoint of death or re-infarction was signiﬁ  -
cantly reduced from an estimated cumulative hazard rate of 
19.0% with placebo to 12.9% with abciximab. The mortality 
rate was reduced from an estimated cumulative hazard rate 
of 14.3% in the placebo arm to 10.9% in the abciximab arm. 
Major bleedings were 2.5 and 2% with and without abcix-
imab, respectively. In the control arm, both the death or MI 
cumulative hazard rate (54 vs 13.5%) and mortality rate (39.7 
vs 10.1%) were 4-fold higher in diabetics than non-diabetics. 
Abciximab provided a signiﬁ  cant beneﬁ  t on the primary end-
point for diabetics. A meta-regression analysis of randomized 
trials with abciximab in the primary PCI setting conﬁ  rmed 
and expanded this observation (De Luca et al 2006).
Principal clinical studies comparing 
abciximab to others GP IIb/IIIa 
inhibitors
Abciximab vs tiroﬁ  ban
In the TARGET trial (Topol et al 2001) (the do Tiroﬁ  ban and 
Abciximab Give Similar Efﬁ  cacy Outcomes study), 5308 
patients scheduled to urgent or elective PCI were enrolled 
and randomized to tiroﬁ  ban (bolus 10 μg/kg and infusion of 
0.15 μg/kg/min) or abciximab (bolus 25 mg/kg and infusion 
0.125 μg/kg). All patients received aspirin, dose-adjusted 
heparin and, when possible, loading dose of clopidogrel of 
300 mg 2–6 hours before the procedure. The primary end 
point, a composite of death, nonfatal MI and urgent target-
vessel revascularization within 30 days after the index pro-
cedure, occurred more frequently in the tiroﬁ  ban group than 
in the abciximab group (7.6% vs 6%, p = 0.03).
The superiority of abciximab was entirely driven by 
a higher rate of peri-procedural MI in the tiroﬁ  ban arm, 
mortality rate and the need for target vessel revasculariza-
tion completely overlapping between the two study arms. 
Interestingly, plotting the incidence of MI in the two study 
groups in the ﬁ  rst 72 hours after randomization (Figure 1), 
it becomes clear that this had already started to diverge in 
the tiroﬁ  ban arm 8 hours after randomization with respect 
to abciximab but after 24 hours the two curves were running 
parallel, which implies that the excess of MI in the tiroﬁ  ban 
group occurred between 8 and 24 hours after randomization. 
Since the occurrence of MI in the trial was deﬁ  ned as the 
ﬁ  nding of levels of the MB isoform of creatine kinase that 
were at least 3 times the upper limit of the normal range in 
2 separate blood samples, which were taken every 6 hours 
Table 2 Abciximab use in clinical trials
Trials Population study Design Key information
EPIC 2099 pts scheduled to high risk 
PCI
Placebo vs only bolus abciximab vs 
bolus + infusion abciximab
Abciximab bolus + infusion 
resulted in a 35% reduction in the 
rate of the primary endpoint
EPISTENT 2399 pts receiving elective or 
urgent PCI
Stent and placebo vs stent and 
abciximab vs POBA and abciximab
Abciximab and stent implantation 
confer complementary long-term 
clinical beneﬁ  ts
EPILOG 2792 pts receiving elective or 
urgent PCI
Heparin vs abciximab + heparin vs 
abciximab + low-dose heparin
Reduction of acute ischemic com-
plications, without increasing the 
risk of hemorrhage
CAPTURE 1050 pts with refractory UA Abciximab vs placebo. PCI was 
scheduled 18–24 h after medica-
tion
Abciximab substantially reduces 
the rate of MI, before, during, and 
after PCI
GUSTO IV-ACS 7800 patients with ACS Placebo (heparin) vs abciximab 
bolus + infusion for 24 h vs abcix-
imab bolus + infusion for 48 h
No difference in 30-day death or 
MI in main cohort and diabetic 
subgroup analysis fails to reach 
statistical signiﬁ  cance
TARGET 5308 patients scheduled to PCI Tiroﬁ  ban (RESTORE regime) vs 
abciximab 
Lower incidence of death, re-MI, 
and TVR in the abciximab group
ISAR-REACT Pts low risk undergoing PCI 600 mg clopidogrel vs 600 mg 
clopidogrel + abciximab
Abciximab offered no clinically 
measurable beneﬁ  t at 30 days
ISAR-REACT 2 2022 pts with ACS undergoing PCI 600 mg clopidogrel vs 600 mg 
clopidogrel + abciximab
Reduction of the risk of adverse 
events in patients with non-STseg-
ment elevation ACS
Abbreviations: ACS, acute coronary syndrome; MI, myocardial infarction; PCI, percutaneous coronary intervention; POBA, percutaneous only ballon angioplasty; 
pts, patients; TVR, target vessel revascularization; UA, unstable angina.Biologics: Targets & Therapy 2008:2(1) 33
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after the index procedure, these ﬁ  ndings altogether strongly 
suggest that the excess of MI in the tiroﬁ  ban arm was indeed 
generated directly during the procedure, a few minutes after 
the bolus of the two drugs were administered. However, 
starting from the ﬁ  rst day after the procedure, the event rate 
in the two groups remained similar, thus diluting the small 
early excess of events in the tiroﬁ  ban arm, which explains 
the ﬁ  nding of a similar overall event rate at 6 and 12 months. 
Several studies (Batchelor et al 2002; Ernst et al 2004) 
showed that, soon after the bolus, the degree of early platelet 
inhibition was higher after abciximab than after tiroﬁ  ban 
(dosage used in the randomized efﬁ  cacy study of tiroﬁ  ban 
for outcomes and restenosis – RESTORE – (The RESTORE 
Investigators 1997) and TARGET studies (Topol et al 2001), 
thus offering more protection during PCI, where iatrogenic 
vessel injury is known to require almost complete platelet 
inhibition. As a consequence of the suboptimal platelet 
inhibition achieved soon after the RESTORE regimen (The 
RESTORE Investigators 1997), subsequent dose-ranging 
studies have led to an increase in the tiroﬁ  ban bolus dose 
from 10 to 25 μg/kg (Schneider et al 2002). The new single 
high-dose bolus (SHDB) of tiroﬁ  ban has been tested and 
compared to abciximab in several studies showing a similar 
level of platelet inhibition soon after the bolus administration 
(SHDB Tiroﬁ  ban and Sirolimus Eluting Stent vs Abcix-
imab and Bare Metal Stent in Acute Myocardial Infarction 
study – STRATEGY – (Valgimigli et al 2005; Campo et al 
2006), Ernst et al (2004), Danzi et al (2004) and equivalent 
outcome at surrogate endpoints as ST-segment resolution in 
the STRATEGY trial (Valgimigli et al 2005; Campo et al 
2006), or change in infarct-zone wall motion score index 
and global LV ejection fraction at 30 days in the study by 
Danzi et al (2004).
In the EVEREST trial (Bolognese et al 2005), NSTEACS 
patients were randomized to upstream vs in-catheteriza-
tion-laboratory initiation of GPIIb/IIIa antagonists. The 
upstream arm received the standard dose of tiroﬁ  ban, as 
used in the PRISM-PLUS trial (the PRISM-PLUS Investi-
gators 1998) (the Platelet Receptor Inhibition in Ischemic 
Syndrome Management in Patients limited by Unstable 
Signs and Symptoms study). The in-catheterization labora-
tory arm received either abciximab or tiroﬁ  ban with high 
dose bolus in a randomized fashion. The results, although 
preliminary, are intriguing. The patients in the upstream 
arm had better myocardial perfusion both on arrival in the 
catheterization laboratory and at the end of their procedure, 
as compared with the higher-dose tiroﬁ  ban and abciximab 
patients, who had therapy initiated in the catheterization 
laboratory. It is plausible that upstream administration 
of GPIIb/IIIa inhibitors may not only prevent thrombus 
formation (and propagation) but may also lead to dissolu-
tion of platelet aggregates. Thus, the upstream use of the 
agent may lead to a lower thrombus load at the start of 
the procedure, hence less potential for distal embolization 
during the procedure.
Abciximab vs eptiﬁ  batide
There no are randomized clinical trials comparing abciximab 
with eptiﬁ  batide, but observational and/or pharmacological 
studies have been conducted and different information may 
be extrapolated.
In the COMPARE trial (Batchelor et al 2002) (the 
Comparison Of Measurements of Platelet Aggregation with 
Aggrastat, Reopro, and Eptiﬁ  batide study), 70 ACS patients 
undergoing PCI were randomized to receive abciximab, 
eptiﬁ  batide, or tiroﬁ  ban at doses used in the EPISTENT (The 
EPISTENT Investigators 1998), PURSUIT (the PURSUIT 
Investigators 1998) (the Platelet Glycoprotein IIb/IIIa in 
Unstable Angina Receptor Suppression Using Integrilin 
Therapy study), and PRISM-PLUS/RESTORE trials, respec-
tively. Platelet aggregation (PA) in response to 20 μmol/L 
of adenosine diphosphate was measured with turbidimetric 
aggregometry early (15 and 30 minutes) and late (4, 12, and 
18–24 hours) after drug initiation. Although all regimens pro-
vided effective platelet inhibition, the tiroﬁ  ban-RESTORE 
regimen produced less inhibition at 15–30 minutes compared 
with abciximab or eptiﬁ  batide. With continued infusion of the 
tiroﬁ  ban-RESTORE regimen, platelet inhibition increased 
Figure 1 Incidence of myocardial infarction in the two study groups of TARGET 
trial (Topol et al 2001).
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to levels comparable to those achieved by abciximab and 
eptiﬁ  batide. In contrast, although the abciximab regimen 
consistently inhibited PA early on, more recovery of PA 
occurred with continued infusion (4–12 hours). Of the 
four regimens evaluated, the eptiﬁ  batide regimen provided 
the most consistent platelet inhibition throughout infusion 
(Figure 2).
Schweiger et al (2003) reported the comparison of 2 
sequential cohorts of consecutive patients undergoing PCI 
who received abciximab or eptiﬁ  batide. A total of 319 
patients were treated with abciximab and 301 with eptiﬁ  -
batide. There were no differences in the incidence of major 
adverse cardiac events in hospital or at 30 days.
Raveendran et al (2007) reported the outcome of 576 
patients underwent primary PCI and treated with GPIIb/IIIa 
receptor antagonists. Abciximab was given to 327 patients 
(57%) and eptiﬁ  batide to 249 (43%). Observed rates of in-
hospital death or MI did not differ between groups. This result 
persisted with adjustment for various patients.
Although these data are interesting, head to head random-
ized controlled trials would be desirable.
Current guidelines
Table 3 summarizes the indication for the use of abciximab 
according to current American and European guidelines. 
As reported, abciximab is currently recommended for the 
administration in the cath-lab immediately before coronary 
revascularization in patients with high risk NSTEACS.
Recently the ACUITY and the ACUITY-TIMING have 
been published (the Acute Catheterization and Urgent Inter-
vention Triage Strategy study) trials (Stone et al 2006a, b. The 
ﬁ  rst study used a 2 × 2 factorial design to compare a heparin 
with or without GPIIb/IIIa inhibition vs bivalirudin with or 
without upstream GPIIb/IIIa inhibition; a third arm tested 
bivalirudin alone with provisional use of GPIIb/IIIa inhibition. 
Authors found that bivalirudin + GPIIb/IIIa inhibitors com-
pared with heparin + GPIIb/IIIa inhibitors was non-inferior on 
the composite of ischemia and major bleeding. As a contrary, 
bivalirudin alone vs heparin + GPIIb/IIIa inhibitors resulted in 
a non-inferior rate of composite ischemia and in a reduction of 
major bleeding. In the second study, two different strategies 
were compared: deferred selective use of GPIIb/IIIa inhibitors 
vs routine upstream administration of GPIIb/IIIa inhibitors. 
They found that a deferred selective use of GP2b/3a inhibi-
tors resulted in a reduced rate of bleeding but a trend towards 
higher ischemic events. Regarding ACUITY (Stone et al 
2006a) and ACUITY-TIMING (Stone et al 2006b) trials, two 
issues should be considered before their results may directly be 
applied to clinical practice: i) the median time between onset 
of medical therapy and catheterization was remarkably short 
(~4 hours), thus the results of ACUITY TIMING cannot be 
extrapolated to those scenarios where longer upstream infu-
sion (24–48 hours) is carried out; ii) in the bivalirudin-alone 
group, the patients who did not receive clopidogrel before PCI 
showed a signiﬁ  cantly worse ischemic outcome.
Safety and tolerability
The major concerns with use of GPIIb/IIIa receptor 
antagonists are the potential risk of major bleeding and 
thrombocytopenia.
Bleeding
Bleeding is generally increased in patients receiving 
GPIIb/IIIa compared to heparin alone, mainly because of 
excessively high heparin dose in the treated arm. Heparin 
dose reduction drastically decreases bleeding rates with no 
impact on ischemic endpoints. Thus, risk of bleeding can 
be reduced by the use of low-dose adjunctive heparin, early 
sheath removal, and meticulous post-procedure care of the 
vascular access site. The increase in bleeding complica-
tions related to use of abciximab might be due to its slowly 
reversible antiplatelet effects, which may be of concern in 
patients in whom an emergency coronary artery bypass graft 
is required. In such a scenario, platelet transfusion may be 
required to control bleeding.
Thrombocytopenia
In clinical trials of abciximab and in subsequent experience, 
it was found that about 1% of patients given this drug expe-
rienced acute, often severe thrombocytopenia (Aster 2005). 
After a second exposure to the drug, the rate for this compli-
cation rises to about 4% (Aster 2005). In some instances, the 
onset of thrombocytopenia may be accompanied by fever, 
dyspnea, hypotension, and even frank anaphylaxis, occur-
ring soon after starting the drug. Although most patients 
with abciximab-associated thrombocytopenia recover 
uneventfully, life-threatening bleeding has been described, 
including intracranial hemorrhage (Aster 2005). Although 
abciximab-induced thrombocytopenia usually occurs within 
a few hours of starting therapy with the drug, a subgroup 
of patients has been described in whom the drop in platelet 
levels occurred 5–8 days after the drug was administered 
(Aster 2005). Direct evidence for the immune destruction 
of platelets in patients who have received abciximab was 
provided by studies showing that a group of patients who 
developed severe thrombocytopenia after a second exposure Biologics: Targets & Therapy 2008:2(1) 35
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Table 3 Indication to use abciximab according to current guidelines
Class ACC/AHA guidelines European task force report
I•    For NSTEACS patients in whom an initial invasive strategy is 
selected. Abciximab is indicated only if there is no appreciable 
delay to angiography and PCI is likely to be performed.
•   High risk NSTEACS patients not pretreated with GP IIb/IIIa 
inhibitors and proceeding PCI.
•   For high risk NSTEACS patients in whom PCI has been selected 
as a post-angiography management strategy, it is reasonable 
administer abciximab if a GP IIb/IIIa has not been started before 
diagnostic angiography.
II •   It is reasonable to start treatment with abciximab as early as 
possible before primary PCI (with or without stenting) in patients 
with STEMI.
•   Abciximab as ancillary therapy during primary PCI.
•   Stable CAD patients treated with PCI of complex lesions, 
threatening/actual vessel closure, visible thrombus, no/slow 
reﬂ  ow.
•   When anatomy is known and PCI planned to be performed 
whitin 24 hours with GPIIb/IIIa inhibitors, most secure evidence 
is for abciximab.
•   Abciximab administration in high risk NSTEACS patients in whom 
bivalirudin was selected as anticoagulant.
III •   Abciximab administration in ACS patients in whom PCI is not 
planned.
•   Abciximab is in fact unnecessary in patients treated with a non 
invasive strategy.
Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; PCI, percutaneous coronary intervention; 
NSTEACS, non ST-segment elevation acute coronary syndrome; STEMI, ST-segment elvation myocardial infarction.
to the drug all had strong IgG and/or IgM antibodies that 
reacted with abciximab-coated platelets in a ﬂ  ow cytomet-
ric assay. There are no published reports characterizing 
antibodies in patients who developed thrombocytopenia 
after a ﬁ  rst exposure to abciximab, although unpublished 
observations suggest that antibodies similar to those found 
in patients given abciximab a second time are responsible 
for platelet destruction in most cases. These antibodies can 
Figure 2 Percentage of patients in whom 80% inhibition of 20 mol/L ADP-induced platelet aggregation was achieved. At 15 minutes, inhibition was signiﬁ  cantly higher in abciximab 
and eptiﬁ  batide groups as compared to tiroﬁ  ban RESTORE group. At 12 hours, inhibition was signiﬁ  cantly higher in eptiﬁ  batide and tiroﬁ  ban RESTORE groups as compared to 
abciximab group.   Adapted with permission from Batchelor WB, Tolleson TR, Huang Y, et al 2002. Randomized comparison of platelet inhibition with abciximab, tiroﬁ  ban and eptiﬁ  -
batide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE Trial. Circulation, 106:1470. Copyright © 2002 Lippincott Williams & Wilkins.
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be found in pretreatment blood samples, indicating that they 
are naturally occurring.
A platelet count should be performed routinely before 
and within 2–6 hours after starting treatment in any patient 
given abciximab to enable the early diagnosis of drug-
induced thrombocytopenia (Aster 2005). Some patients who 
develop thrombocytopenia are asymptomatic or exhibit only 
scattered petechial hemorrhages. Others experience bleeding 
from sites of catheterization, gastro-intestinal hemorrhage, 
or hematoma formation. Because the function of platelets 
remaining in the circulation is impaired by the inhibitor, all 
patients with this complication should be considered to be 
at risk for bleeding, and those with signiﬁ  cant hemorrhage 
should be given platelet transfusions.
Patients who have received abciximab are at risk for a 
longer period of time because platelet function is impaired 
for up to 1 week, and thrombocytopenia sometimes persists 
for 3–5 days. On the basis of limited experience, it appears 
that patients who are sensitive to abciximab can safely receive 
tiroﬁ  ban or eptiﬁ  batide at a later time. It is likely that the 
converse is true, but this has not yet been documented.
Contraindications
The contraindications to use of abciximab are generally 
similar to those of thrombolytic agents and are summarized 
in Table 4.
Novel approaches to use abciximab
Abciximab-coated stent
Differently from other platelet GPIIb/IIIa receptor blockers, 
abciximab binds to MAC-1 (CD11b/18) on vascular endo-
thelial cells and macrophages, thereby inhibiting inﬂ  amma-
tory responses and smooth muscle cell proliferation after 
vascular injury. Furthermore, abciximab is known to bind 
to the vitronectin receptors found on platelets and vascular 
endothelial and smooth muscle cells and exert an inhibitory 
effect on migration and proliferation of smooth muscle cells 
after acute vessel injury. Thus, abciximab-coated stents have 
been created, on the hypothesis of their inhibitory effects in 
coronary restenosis and their prevention effect in subacute stent 
thrombosis. Previous studies (Hong et al 2004) demonstrated 
that abciximab-coated stents were safe and effective in the 
prevention of coronary restenosis in humans. Abciximab-coated 
stents have been tested also in 96 patients with acute MI (Kim 
et al 2006) treated with primary PCI and randomly allocated 
into 2 groups: group I received abciximab-coated stents, and 
group II received bare metal stents. One patient in group II had 
reinfarction and target lesion reintervention during hospital stay. 
At coronary angiography follow-up late loss was signiﬁ  cantly 
lower in group I than group II. In-stent restenosis rate was lower 
in group I than group II. During 1-year follow-up, 2 patients in 
group II (4.1%) had MI, whereas no patients in group I suffered 
MI. Target lesion revascularization and total major adverse 
cardiac events rates were lower in group I than in group II 
(10.4% vs 20.8%, p = 0.261, and 10.4% vs 25.0%, p = 0.107, 
respectively). It is important to note, in this study, the absence of 
episodes of acute MI by acute or subacute thrombotic occlusion 
during 1-year clinical follow-up in the patients who received 
abciximab-coated stents. The sample size of the study was 
small, but it is plausible to speculate that platelet aggregation 
was effectively inhibited with use of abciximab, and this effect 
could be maintained for a long-term period.
Bolus-only use
Traditionally, abciximab is administered as an intravenous 
bolus, followed by a prolonged infusion (12 hours). Many 
patients undergoing PCI (both in the United States and world-
wide) do not receive a GPIIb/IIIa inhibitors, in part owing to 
concerns about bleeding and cost. In the present era of oral 
thienopyridines, where patients are preloaded with a high 
dose of clopidogrel (300–600 mg) in order to achieve an anti-
platelet effect within 2–4 hours, the relevance of a prolonged 
abciximab infusion may be questionable, particularly given 
the widespread use of stents that have virtually eliminated the 
problem of abrupt closure. Moreover, the bolus of abciximab 
represents ~75% of the total dose, and pharmacological data 
have shown that a single bolus (0.25 mg/kg) of abciximab 
induces 80% of platelet aggregation inhibition and that 
this effect is prolonged for several hours. The prolonged 
abciximab infusion, as opposed to bolus-only administra-
tion, may contribute to increased bleeding complications 
and thrombocytopenia, without an incremental anti-ischemic 
beneﬁ  t. The avoidance of prolonged infusion of abciximab 
has the potential to not only reduce vascular complications, 
but also to reduce the length of hospital stay and total cost 
of the procedure.
Marmur et al (2006) retrospectively analyzed consecu-
tive patients (n = 1001) who underwent PCI and received an 
unfractionated heparin and bolus-only GPIIb/IIIa inhibitors 
regimen. All patients received clopidogrel and aspirin prior 
to PCI. Eptiﬁ  batide was used in the 58.3% of the cases, 
abciximab in the 37.3%, and tiroﬁ  ban in the 4.3%. A bolus-
only GPIIb/IIIa inhibitors strategy appears to maintain the 
anti-ischemic beneﬁ  ts, with the added beneﬁ  t of reduced 
bleeding complications and the potential for reduced cost 
and shortened length of hospital stay.Biologics: Targets & Therapy 2008:2(1) 37
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In the EASY trial (Bertrand et al 2006) (the Early 
Discharge after Transradial Stenting of Coronary Arteries 
study), 1005 patients were randomized after a bolus of abcix-
imab and uncomplicated transradial percutaneous coronary 
stent implantation either to same-day home discharge and 
no infusion of abciximab or to overnight hospitalization 
and a standard 12-hour infusion of abciximab. The primary 
composite end point of the study was the 30-day incidence 
of any of the following events: death, MI, urgent revascu-
larization, major bleeding, repeat hospitalization, access 
site complications, and severe thrombocytopenia. They 
found that same-day home discharge after uncomplicated 
transradial coronary stenting and bolus only of abciximab 
is not clinically inferior, in a wide spectrum of patients, to 
the standard overnight hospitalization and a bolus followed 
by a 12-hour infusion.
In the EPIC trial, 2099 patients scheduled to high-risk 
PCI were enrolled and randomized to 3 treatment arms: 
bolus and 12-hour infusion of placebo, abciximab bolus of 
0.25 mg/kg plus 12-hour placebo infusion, and abciximab 
bolus plus 12-hour infusion (10 μg/min). It is important to 
note that thienopyridines were not administered to patients 
in the EPIC as protocol mandated balloon angioplasty 
only. Accordingly, stent was used in the EPIC only to treat 
imminent or complete abrupt closure of the vessel undergo-
ing angioplasty. The primary end point of the EPIC trial 
was a composite of death, MI, or urgent intervention during 
the ﬁ  rst 30 days after randomization. Recently, an analysis 
of the EPIC outcomes at 6-hour intervals during the ﬁ  rst 24 
hours after PCI to identify any early beneﬁ  t derived from the 
abciximab bolus-only arm has been published (Marmur et al 
2006). This analysis demonstrates a signiﬁ  cant reduction in 
the composite end point of death, MI, or urgent intervention 
at 6 hours in the abciximab bolus-only group compared with 
the placebo group. After 6 hours and throughout the ﬁ  rst 24 
hours post-procedure, a numerical reduction was apparent, 
but statistical signiﬁ  cance was not achieved. The fact that a 
bolus-only strategy appears to be effective in the ﬁ  rst 6 hours 
may be relevant in the context of stenting and routine admin-
istration of a loading dose of clopidogrel.
Intracoronary use
All clinical trials studied solely the intravenous administration 
of abciximab and there is only limited information on the efﬁ  -
cacy of intracoronary administration of abciximab. In patients 
with ACS, intracoronary administration of abciximab with very 
high local concentrations of the antibody may be favorable 
in dissolution of thrombi and microemboli with subsequent 
better and faster recovery of myocardial microcirculation and 
reduction of major adverse cardiac events (MACE). Wöhrle 
et al (2003) reported a series of 403 consecutive patients with 
unstable angina or acute MI undergoing emergency coronary 
intervention retrospectively stratiﬁ  ed according to the method 
of application of abciximab (20 mg bolus of abciximab was 
given intravenously in 109 patients and intracoronarily in 
294 patients, followed by 12 hours of intravenous infusion of 
10 mg in both groups). At 30 days, the incidence of MACE 
(death, MI, urgent revascularization) was signiﬁ  cantly lower 
in the patients with intracoronary compared with intravenous 
administration of abciximab (10.2% vs 20.2%; p = 0.008), 
which was independent from stenting in multivariate analysis. 
The effect was most pronounced in patients with pre-procedural 
TIMI 0/1 ﬂ  ow (MACE: intracoronary 11.8% vs intravenous 
27.5%, p = 0.002).
Burzotta et al (2003), with their angiographic data in a 
limited subset of patients, extended the ﬁ  ndings of Wöhrle, 
suggesting that in patients with ACS, the reduction of angio-
graphically evident thrombus obtained with intracoronary 
administration of abciximab translates into an acute improve-
ment of coronary blood ﬂ  ow.
Conclusions
Several randomized trials have reported the ability of 
abciximab to reduce death or MI when used as adjunctive 
therapy to PCI. Accordingly, abciximab is recommended 
Table 4 Contraindications to abciximab use
Absolute contraindications
Intracranial aneurysm
Artery-venous malformation
Active major bleeding
Coagulopathy (eg, hemophilia)
Intracranial mass
Stroke in the previous 30 days
Hemorrhagic stroke
Surgery or trauma in the preceding 6 weeks
Thrombocytopenia
Concurrent dextran therapy
Murine protein hypersensitivity
Vasculitis
Relative contraindications
Concurrent anticoagulation therapy (eg, with warfarin)
Breast feeding
Pregnancy
Uncontrolled hypertension (SBP 200 mmHg, DBP 110 mmHg)
Thrombolytic therapy
Abciximab hypersensitivity
Abbrevations: DBP, diastolic blood pressure; SBP, systolic blood pressure.Biologics: Targets & Therapy 2008:2(1) 38
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by the American College of Cardiology/American Heart 
Association and European Society of Cardiology guidelines 
(Braunwald et al 2002; Stone et al 2006a; Task force for 
percutaneous coronary intervention of the European Society 
of Cardiology 2005; Task force for diagnosis and treatment 
of non ST-segment elavation acute coronary syndromes 
2007; ACC/AHA 2007). There is increasing evidence that 
treatment with clopidogrel prior to PCI prevents postproce-
dural ischemic complications. Several studies have shown 
that a 600-mg loading dose of clopidogrel, compared with 
the usual 300-mg dose, is as safe and is signiﬁ  cantly more 
rapidly acting. However, it is known that the antiplatelet 
effect provided by 600 mg of clopidogrel is not sufﬁ  cient 
for patients with STEMI or moderate-high risk ACS under-
going PCI (Kastrati et al 2006). Thus, GPIIb/IIIa inhibitors 
show a critical role in the current management of high risk 
patients. It is plausible that in the future the abciximab 
bolus-only scheme for facilitating PCI may become a more 
widespread choice to maintain efﬁ  cacy while minimizing 
safety and costs. Randomized controlled trials are currently 
underway.
Current data suggest that there are no differences between 
the three GPIIb/IIIa inhibitors approved for clinical use in 
terms of degree of platelet inhibition, particularly after the 
revision of the tiroﬁ  ban bolus dose. Nevertheless, abciximab 
still today remains the GPIIb/IIIa inhibitor with greater evi-
dence of beneﬁ  t from randomized clinical trials showing a 
signiﬁ  cant and consistent reduction of death and reinfarction 
in high risk patients undergoing PCI.
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